Patents by Inventor Arnd Steuernagel
Arnd Steuernagel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10975359Abstract: The present invention relates to a method of producing a polyomavirus or polyomavirus-derived virus-like particle (vlp) carrying on its surface at least one targeting molecule that binds to a cell of interest. Furthermore, the present invention relates to a composition comprising such a polyomavirus or polyomavirus-derived vlp and to the use of the polyomavirus or polyomavirus-derived vlp of the invention or the composition of the invention for use as a medicament. The present invention further relates to a kit comprising the polyomavirus or polyomavirus-derived vlp or the composition of the invention.Type: GrantFiled: February 1, 2018Date of Patent: April 13, 2021Assignee: Deutsches Primatenzentrum GmbH Leibniz-Institut für PrimatenforschungInventors: Jens Gruber, Stefan Schneider, Ellen Eckermann-Felkl, Alina Mosblech, Arnd Steuernagel, Dennis Wegener, Julian Plaga
-
Publication number: 20190352617Abstract: The present invention relates to a method of producing a polyomavirus or polyomavirus-derived virus-like particle (VLP) carrying on its surface at least one targeting molecule that binds to a cell of interest, the method comprising the step of contacting the polyomavirus or polyomavirus-derived VLP with (i) the targeting molecule, wherein the at least one targeting molecule is glycosylated with at least one glycosyl residue that is recognised by the polyomavirus or polyomavirus-derived VLP; or (ii) a first interaction molecule, wherein the first interaction molecule is glycosylated with at least one glycosyl residue that is recognised by the polyomavirus or polyomavirus-derived VLP; and the at least one targeting molecule, wherein the at least one targeting molecule is conjugated to a second interaction molecule capable of interacting with the first interaction molecule.Type: ApplicationFiled: February 1, 2018Publication date: November 21, 2019Inventors: Jens Gruber, Stefan Schneider, Ellen Eckermann-Felkl, Alina Mosblech, Arnd Steuernagel, Dennis Wegener, Julian Plaga
-
Patent number: 9492572Abstract: The present invention refers to novel dimeric proteins obtained from modified ubiquitin capable of binding targets with high affinity. The novel dimeric binding proteins comprise a combination of amino acid substitutions and at least one insertion of amino acids in one of the monomers. The invention is further directed to the use of said proteins in medical diagnosis or treatment methods.Type: GrantFiled: June 15, 2012Date of Patent: November 15, 2016Assignee: Scil Proteins GmbHInventors: Joerg Nerkamp, Eva Bosse-Doenecke, Arnd Steuernagel, Ulrike Fiedler, Markus Fiedler
-
Patent number: 8957020Abstract: This invention relates to the use of nucleic acid sequences of the MAP kinase-interacting kinase (Mnk) gene family and amino acid sequences encoded thereby, and to using these sequences or effectors of Mnk nucleic acids or polypeptides, particularly Mnk kinase inhibitors and activators, in the diagnosis and treatment of diseases and disorders related to body-weight regulation and thermogenesis. One aspect of the disclosure encompasses methods of identifying an animal or human having an elevated probability of having or developing obesity, the method comprising: (a) obtaining a biological sample from an animal or human subject; and (b) determining from the biological sample whether the animal or human subject has a genetic variant of an Mnk2 and/or Mnk1 gene or a homolog thereof, or an expression product of said Mnk2 and/or Mnk1 gene or homolog thereof, wherein said genetic variant is associated with an elevated probability of having or developing obesity.Type: GrantFiled: September 26, 2011Date of Patent: February 17, 2015Assignee: Boehringer Ingelheim International GmbHInventors: Arnd Steuernagel, Karsten Eulenberg, Guenter Broenner, Thomas Ciossek, Bettina Rudolph, Dorothea Rudolph, Funmi Belgore, Stefan Jaekel, Christoph Meyer
-
Patent number: 8921304Abstract: The present invention refers to novel hetero-multimeric proteins obtained from modified ubiquitin capable of binding the extradomain B of fibronectin (ED-B) with high affinity. Furthermore, the invention refers to fusion proteins comprising said recombinant protein fused to a pharmaceutically and/or diagnostically active component. The invention is further directed to the use of said proteins in medical treatment methods.Type: GrantFiled: December 14, 2010Date of Patent: December 30, 2014Assignee: Scil Proteins GmbHInventors: Arnd Steuernagel, Erik Fiedler, Markus Fiedler, Anja Kunert, Joerg Nerkamp, Thomas Goettler, Manja Gloser, Ilka Haenssgen
-
Patent number: 8828934Abstract: This invention relates to the use of nucleic acid sequences of the MAP kinase-interacting kinase (Mnk) gene family and amino acid sequences encoded thereby, and to using these sequences or effectors of Mnk nucleic acids or polypeptides, particularly Mnk kinase inhibitors and activators, in the diagnosis and treatment of diseases and disorders related to body-weight regulation and thermogenesis. One aspect of the disclosure encompasses methods of identifying an animal or human having an elevated probability of having or developing a pancreatic malfunction, the method comprising: (a) obtaining a biological sample from an animal or human subject; and (b) determining from the biological sample whether the subject has a genetic variant of an Mnk2 and/or Mnk1 gene or a homolog thereof, or an expression product of said Mnk2 and/or Mnk1 gene or homolog thereof, wherein said genetic variant is associated with an elevated probability of having or developing a pancreatic malfunction.Type: GrantFiled: September 26, 2011Date of Patent: September 9, 2014Assignee: Boehringer Ingelheim International GmbHInventors: Arnd Steuernagel, Karsten Eulenberg, Guenter Broenner, Thomas Ciossek, Bettina Rudolph, Dorothea Rudolph, Funmi Belgore, Stefan Jaekel, Christoph Meyer
-
Patent number: 8748351Abstract: The present invention refers to a method for identifying hetero-multimeric ubiquitins with binding capability to a ligand. Furthermore, the invention provides DNA libraries encoding for a population of said hetero-multimeric ubiquitins as well as protein libraries obtained by expression of said DNA libraries, cells and phages containing said DNA or proteins, polynucleotides encoding for said fusion proteins and vectors comprising said polynucleotides. Further new binding proteins based on hetero-multimeric ubiquitin being able to bind specifically with high affinity to selected ligands are provided.Type: GrantFiled: December 14, 2010Date of Patent: June 10, 2014Assignee: Scil Proteins GmbHInventors: Anja Kunert, Jörg Narkamp, Arnd Steuernagel, Markus Fiedler, Erik Fiedler, Thomas Göttler
-
Publication number: 20140127129Abstract: The present invention refers to novel dimeric proteins obtained from modified ubiquitin capable of binding targets with high affinity. The novel dimeric binding proteins comprise a combination of amino acid substitutions and at least one insertion of amino acids in one of the monomers. The invention is further directed to the use of said proteins in medical diagnosis or treatment methods.Type: ApplicationFiled: June 15, 2012Publication date: May 8, 2014Applicant: Scil Proteins GmbHInventors: Joerg Nerkamp, Eva Bosse-Doenecke, Arnd Steuernagel, Ulrike Fiedler, Markus Fiedler
-
Publication number: 20130157878Abstract: The present invention refers to a method for identifying hetero-multimeric ubiquitins with binding capability to a ligand. Furthermore, the invention provides DNA libraries encoding for a population of said hetero-multimeric ubiquitins as well as protein libraries obtained by expression of said DNA libraries, cells and phages containing said DNA or proteins, polynucleotides encoding for said fusion proteins and vectors comprising said polynucleotides. Further new binding proteins based on hetero-multimeric ubiquitin being able to bind specifically with high affinity to selected ligands are provided.Type: ApplicationFiled: December 14, 2010Publication date: June 20, 2013Inventors: Anja Kunert, Jörg Narkamp, Arnd Steuernagel, Markus Fiedler, Erik Fiedler, Thomas Göttler
-
Publication number: 20130011334Abstract: The present invention refers to novel hetero-multimeric proteins obtained from modified ubiquitin capable of binding the extradomain B of fibronectin (ED-B) with high affinity. Furthermore, the invention refers to fusion proteins comprising said recombinant protein fused to a pharmaceutically and/or diagnostically active component. The invention is further directed to the use of said proteins in medical treatment methods.Type: ApplicationFiled: December 14, 2010Publication date: January 10, 2013Inventors: Arnd Steuernagel, Erik Fiedler, Markus Fiedler, Anja Kunert, Joerg Nerkamp, Thomas Goettler, Manja Gloser, Ilka Haenssgen
-
Publication number: 20120301393Abstract: The present invention refers to novel recombinant proteins obtained from modified ubiquitin capable of binding the extradomain B of fibronectin (ED-B). Furthermore, the invention refers to fusion proteins comprising said recombinant protein fused to a pharmaceutically and/or diagnostically active component.Type: ApplicationFiled: December 14, 2010Publication date: November 29, 2012Inventors: Arnd Steuernagel, Erik Fiedler, Markus Fiedler, Anja Kunert, Joerg Nerkamp, Thomas Goettler, Manja Gloser, Ilka Haenssgen
-
Publication number: 20120045451Abstract: This invention relates to the use of nucleic acid sequences of the MAP kinase-interacting kinase (Mnk) gene family and amino acid sequences encoded thereby, and to using these sequences or effectors of Mnk nucleic acids or polypeptides, particularly Mnk kinase inhibitors and activators, in the diagnosis and treatment of diseases and disorders related to body-weight regulation and thermogenesis. One aspect of the disclosure encompasses methods of identifying an animal or human having an elevated probability of having or developing obesity, the method comprising: (a) obtaining a biological sample from an animal or human subject; and (b) determining from the biological sample whether the animal or human subject has a genetic variant of an Mnk2 and/or Mnk1 gene or a homolog thereof, or an expression product of said Mnk2 and/or Mnk1 gene or homolog thereof, wherein said genetic variant is associated with an elevated probability of having or developing obesity.Type: ApplicationFiled: September 26, 2011Publication date: February 23, 2012Applicant: DeveloGen Aktiengesellschaft fuer Entwicklungsbiologische ForschungInventors: Arnd Steuernagel, Karsten Eulenberg, Guenter Broenner, Thomas Ciossek, Bettina Rudolph, Dorothea Rudolph, Funmi Belgore, Stefan Jakel, Christoph Meyer
-
Publication number: 20120045452Abstract: This invention relates to the use of nucleic acid sequences of the MAP kinase-interacting kinase (Mnk) gene family and amino acid sequences encoded thereby, and to using these sequences or effectors of Mnk nucleic acids or polypeptides, particularly Mnk kinase inhibitors and activators, in the diagnosis and treatment of diseases and disorders related to body-weight regulation and thermogenesis. One aspect of the disclosure encompasses methods of identifying an animal or human having an elevated probability of having or developing a pancreatic malfunction, the method comprising: (a) obtaining a biological sample from an animal or human subject; and (b) determining from the biological sample whether the subject has a genetic variant of an Mnk2 and/or Mnk1 gene or a homolog thereof, or an expression product of said Mnk2 and/or Mnk1 gene or homolog thereof, wherein said genetic variant is associated with an elevated probability of having or developing a pancreatic malfunction.Type: ApplicationFiled: September 26, 2011Publication date: February 23, 2012Applicant: DeveloGen Aktiengesellschaft fuer Entwicklungsbiologische ForschungInventors: Arnd Steuernagel, Karsten Eulenberg, Günter Brönner, Thomas Ciossek, Bettina Rudolph, Dorothea Rudolph, Funmi Belgore, Stefan Jäkel, Christoph Meyer
-
Patent number: 8076098Abstract: The present invention discloses Mnk homologous proteins regulating the energy homeostasis, the metabolism of triglycerides, and/or is contributing to membrane stability and/or function of organelles, and polynucleotides, which identify and encode the proteins disclosed in this invention. The invention also relates to the use of these sequences in the diagnosis, study, prevention, and treatment of diseases and disorders related to body-weight regulation and thermogenesis, for example, but not limited to, metabolic diseases such as obesity, as well as related disorders such as eating disorder, cachexia, diabetes mellitus, hypertension, coronary heart disease, hypercholesterolemia, dyslipidemia, osteoarthritis, gallstones, and sleep apnea, and disorders related to ROS defence, such as diabetes mellitus, neurodegenerative disorders, and cancer, e.g. cancers of the reproductive organs, and others.Type: GrantFiled: July 16, 2008Date of Patent: December 13, 2011Assignee: Boehringer Ingelheim International GmbHInventors: Arnd Steuernagel, Karsten Eulenberg, Guenter Broenner, Thomas Ciossek, Bettina Rudolph, Dorothea Rudolph, Funmi Belgore, Stefan Jaekel, Christoph Meyer
-
Publication number: 20090170095Abstract: The present invention discloses Mnk homologous proteins regulating the energy homeostasis, the metabolism of triglycerides, and/or is contributing to membrane stability and/or function of organelles, and polynucleotides, which identify and encode the proteins disclosed in this invention. The invention also relates to the use of these sequences in the diagnosis, study, prevention, and treatment of diseases and disorders related to body-weight regulation and thermogenesis, for example, but not limited to, metabolic diseases such as obesity, as well as related disorders such as eating disorder, cachexia, diabetes mellitus, hypertension, coronary heart disease, hypercholesterolemia, dyslipidemia, osteoarthritis, gallstones, and sleep apnea, and disorders related to ROS defence, such as diabetes mellitus, neurodegenerative disorders, and cancer, e.g. cancers of the reproductive organs, and others.Type: ApplicationFiled: July 16, 2008Publication date: July 2, 2009Applicant: DeveloGen Aktiengesellschaft fuer Entwicklungsbiologische ForschungInventors: Arnd Steuernagel, Karsten Eulenberg, Gunter Broenner, Thomas Clossek, Bettina Rudoplh, Dorothea Rudolph, Funmi Belgore, Stefan Jakel, Christoph Meyer
-
Publication number: 20080226638Abstract: Provided herein are methods for the treatment of metabolism disorders by delivering a therapeutically effective amount of a modulator of a SOUP1 polypeptide. The invention also relates to a nucleic acid molecule encoding a polypeptide contributing to membrane stability and/or function of organelles.Type: ApplicationFiled: January 5, 2007Publication date: September 18, 2008Applicant: DEVELOGEN AG FUR ENTWICKLUNGSBIOLOGISCHE FORSCHUNGInventors: Arnd Steuernagel, Gunter Bronner, Cord Dohrmann, Thomas Ciossek, Roland Wehr, Bettina Rudolph, Dorothea Rudolph
-
Patent number: 7404952Abstract: The present invention discloses three novel proteins regulating the energy homeostasis and the metabolism of triglycerides, and polynucleotides, which identify and encode the proteins disclosed in this invention. The invention also relates to vectors, host cells, antibodies, and recombinant methods for producing the polypeptides and polynucleotides of the invention. The invention also relates to the use of these sequences in the diagnosis, study, prevention, and treatment of diseases and disorders related to body-weight regulation, for example, but not limited to, metabolic diseases such as obesity, as well as related disorders such as adipositas, eating disorders, wasting syndromes (cachexia), pancreatic dysfunctions (such as diabetes mellitus), hypertension, pancreatic dysfunctions, arteriosclerosis, coronary artery disease (CAD), coronary heart disease, hypercholesterolemia, dyslipidemia, osteoarthritis, gallstones, cancer, e.g. cancers of the reproductive organs, sleep apnea, and others.Type: GrantFiled: December 5, 2006Date of Patent: July 29, 2008Assignee: Develogen Aktiengesellschaft fur Entwicklungsbiologische ForshungInventors: Karsten Eulenberg, Gunter Bronner, Thomas Ciossek, Thomas Hader, Arnd Steuernagel
-
Publication number: 20080075713Abstract: The present invention discloses three novel proteins regulating the energy homeostasis and the metabolism of triglycerides, and polynucleotides, which identify and encode the proteins disclosed in this invention. The invention also relates to vectors, host cells, antibodies, and recombinant methods for producing the polypeptides and polynucleotides of the invention. The invention also relates to the use of these sequences in the diagnosis, study, prevention, and treatment of diseases and disorders related to body-weight regulation, for example, but not limited to, metabolic diseases such as obesity, as well as related disorders such as adipositas, eating disorders, wasting syndromes (cachexia), pancreatic dysfunctions (such as diabetes mellitus), hypertension., pancreatic dysfunctions, arteriosclerosis, coronary artery disease (CAD), coronary heart disease, hypercholesterolemia, dyslipidemia, osteoarthritis, gallstones, cancer, e.g. cancers of the reproductive organs, sleep apnea, and others.Type: ApplicationFiled: December 5, 2006Publication date: March 27, 2008Inventors: Karsten Eulenberg, Gunter Bronner, Thomas Ciossek, Thomas Hader, Arnd Steuernagel
-
Publication number: 20070185048Abstract: The present invention discloses three novel proteins regulating the energy homeostasis and the metabolism of triglycerides, and polynucleotides, which identify and encode the proteins disclosed in this invention. The invention also relates to vectors, host cells, antibodies, and recombinant methods for producing the polypeptides and polynucleotides of the invention. The invention also relates to the use of these sequences in the diagnosis, study, prevention, and treatment of diseases and disorders related to body-weight regulation, for example, but not limited to, metabolic diseases such as obesity, as well as related disorders such as adipositas, eating disorders, wasting syndromes (cachexia), pancreatic dysfunctions (such as diabetes mellitus), hypertension, pancreatic dysfunctions, arteriosclerosis, coronary artery disease (CAD), coronary heart disease, hypercholesterolemia, dyslipidemia, osteoarthritis, gallstones, cancer, e.g. cancers of the reproductive organs, sleep apnea, and others.Type: ApplicationFiled: December 5, 2006Publication date: August 9, 2007Inventors: Karsten Eulenberg, Gunter Bronner, Thomas Ciossek, Thomas Hader, Arnd Steuernagel
-
Patent number: 7211563Abstract: The present invention discloses three novel proteins regulating the energy homeostasis and the metabolism of triglycerides, and polynucleotides, which identify and encode the proteins disclosed in this invention. The invention also relates to vectors, host cells, antibodies, and recombinant methods for producing the polypeptides and polynucleotides of the invention. The invention also relates to the use of these sequences in the diagnosis, study, prevention, and treatment of diseases and disorders related to body-weight regulation, for example, but not limited to, metabolic diseases such as obesity, as well as related disorders such as adipositas, eating disorders, wasting syndromes (cachexia), pancreatic dysfunctions (such as diabetes mellitus), hypertension, pancreatic dysfunctions, arteriosclerosis, coronary artery disease (CAD), coronary heart disease, hypercholesterolemia, dyslipidemia, osteoarthritis, gallstones, cancer, e.g. cancers of the reproductive organs, sleep apnea, and others.Type: GrantFiled: March 28, 2002Date of Patent: May 1, 2007Assignee: Develogen Aktiengesellschaft fur Entwicklungsbiologische ForschungInventors: Karsten Eulenberg, Günter Brönner, Thomas Ciossek, Thomas Häder, Arnd Steuernagel